Efficacy and tolerability of antidepressants in the treatment of adolescents and young adults with depression and substance use disorders: a systematic review and meta‐analysis

Zhou, Xinyu; Qin, Bin; Giovane, Cinzia Del; Pan, Junxi; Gentile, Salvatore; Liu, Yiyun; Lan, Xinghui; Ji, Yu; Xie, Peng

doi:10.1111/add.12698

Cited by 34 publications

(22 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Meta-analysis and reviews that integrate results of clinical studies in which patients with AUD and depression were treated with ADs show drug-dependent and inconclusive results. Some findings showed that SSRIs adequately treat depressive symptomatology in individuals with AUD and depression [85][86][87], while others showed that SSRIs were not more effective than placebo in treating comorbid patients [88,89]. In relation, it has also been seen that SSRIs would not show greater effects than TCAs [90].…”

Section: Clinical Evidence Of Antidepressant Treatment Improves Deprementioning

confidence: 99%

Rethinking the Use of Antidepressants to Treat Alcohol Use Disorders and Depression Comorbidity: The Role of Neurogenesis

Ballesta¹,

Alén²,

Fonseca³

et al. 2019

Antidepressants - Preclinical, Clinical and Translational Aspects

View full text Add to dashboard Cite

Patients with alcohol use disorders (AUDs) are frequently treated with antidepressant drugs (ADs), but clinical evidence of their efficacy is contradictory. Considering that ADs are thought to produce their therapeutic effects partially by increasing hippocampal plasticity and neurogenesis (HN), and that both AUDs and depression share a potential for the disruption of these neuroplastic processes, one could reasonably wonder whether the poor efficacy of AD treatment could be explained by the inability of these drugs to exert their proper action in patients suffering from AUD or depression. In order to further clarify this question, this chapter aims to examine available data regarding the effect of ADs on behavioral and HN alterations related to alcohol abstinence, as a key period in which the treatment would be implemented and in which their potential effects on alcohol-related problems remain under controversy.

show abstract

Section: Clinical Evidence Of Antidepressant Treatment Improves Deprementioning

confidence: 99%

Rethinking the Use of Antidepressants to Treat Alcohol Use Disorders and Depression Comorbidity: The Role of Neurogenesis

Ballesta¹,

Alén²,

Fonseca³

et al. 2019

Antidepressants - Preclinical, Clinical and Translational Aspects

View full text Add to dashboard Cite

show abstract

“…Medication assisted and physiologic therapy [90] Report of a review of studies of transcranial magnetic stimulation on addiction [62] A review outcome studies of the effectiveness of EEG Biofeedback for treatment of substance use disorder [65] Evaluated the use of transcranial magnetic stimulation on smoking cueinduced craving [91] Evaluated the use of selective serotonin reuptake inhibitors for substance use disorders.…”

Section: References Notesmentioning

confidence: 99%

Substance Abuse Therapeutics

Mills¹

2016

Recent Advances in Drug Addiction Research and Clinical Applications

View full text Add to dashboard Cite

This chapter provides a broad overview of therapies for substance abuse. These therapies are understood in the context of the history of drug use in the United States and factors that influenced the expansion and regulation of substance use. This is followed by a discussion of how the complexity of these factors was associated with difficulties in understanding substance misuse and created challenges to the creation of effective treatment systems. The chapter reviews the moral and disease models of addiction before discussing the diagnosis of substance-related disorders. The chapter describes major treatment approaches and their efficacy.

show abstract

“…In terms of depression, Zhou and colleagues (58) included five RCTs in a meta-analysis comparing antidepressants, namely selective serotonin reuptake inhibitors, to placebo for treatment of co-occurring unipolar depression and SUD (e.g., alcohol, cannabis, and other substances) in youth aged ≤ 25 years. Overall, antidepressant medication produced modest reductions in depressive symptoms, but improvement in substance use outcomes did not surpass the effect of placebo.…”

Section: Introductionmentioning

confidence: 99%

Emerging Pharmacologic Treatments for Adolescent Substance Use: Challenges and New Directions

Miranda

Treloar

2016

Curr Addict Rep

View full text Add to dashboard Cite

Adolescence is a key period in the development of substance use and misuse. Substance use typically begins during adolescence and prevalence rates for many substance use disorders peak before age 21 years. Yet, despite clinical demand, treatments for youth rely almost entirely on psychosocial interventions that yield only modest benefit. One potential way to improve treatment effects is to augment the best available psychosocial interventions with pharmacotherapy. Although pharmacotherapy research has advanced care for adults with substance use disorders, no medication is indicated for adolescents and controlled trials with teenagers are scant. Optimizing treatments for youth will require closing this important gap in medication development research. In this paper we review the paucity of pharmacotherapy research for adolescent substance misuse, and we discuss how we can leverage human laboratory paradigms and technology to advance our understanding regarding if and how medications may improve treatment options for youths.

show abstract

Efficacy and tolerability of antidepressants in the treatment of adolescents and young adults with depression and substance use disorders: a systematic review and meta‐analysis

Abstract: Antidepressant medication has a small overall effect in reducing depression in young patients with combined depressive and substance-use disorders, but does not appear to improve substance use outcomes.

Cited by 34 publications

References 45 publications

Rethinking the Use of Antidepressants to Treat Alcohol Use Disorders and Depression Comorbidity: The Role of Neurogenesis

Rethinking the Use of Antidepressants to Treat Alcohol Use Disorders and Depression Comorbidity: The Role of Neurogenesis

Substance Abuse Therapeutics

Emerging Pharmacologic Treatments for Adolescent Substance Use: Challenges and New Directions

Contact Info

Product

Resources

About